This award supports clinical trials that can significantly impact ovarian cancer treatment or management. Funded projects may test new drugs, biologics, devices, clinical guidance, or emerging technologies. Trials can range from small proof-of-concept studies to large-scale trials assessing efficacy in patient populations.
Open to any type of entity, with no specific restrictions stated. Eligibility may be subject to additional clarifications in the full announcement.
